Norris R J
Medical Affairs Division, Rorer International Pharmaceuticals, Division of Rorer Group Inc., Fort Washington, Pennsylvania 19034.
Am J Cardiol. 1988 Feb 10;61(5):14C-22C. doi: 10.1016/0002-9149(88)90479-1.
Celiprolol is a new generation beta blocker with a novel profile of activity that includes a high degree of cardioselectivity, partial beta 2-agonist activity, and possibly a degree of direct peripheral vasodilation. The drug is hydrophilic, with fewer cardiodepressant effects than other beta antagonists. These ancillary properties may make celiprolol a more suitable beta blocker for use in a broader range of hypertensive patients than conventional agents, and additional work is ongoing in patients with obstructive airways disease, peripheral vascular disorders and those with impaired cardiac function to substantiate and extend current findings.
塞利洛尔是一种新一代的β受体阻滞剂，具有独特的活性特征，包括高度的心脏选择性、部分β2激动剂活性以及可能的一定程度的直接外周血管舒张作用。该药物具有亲水性，与其他β受体拮抗剂相比，心脏抑制作用较少。这些辅助特性可能使塞利洛尔比传统药物更适合用于更广泛的高血压患者，并且针对阻塞性气道疾病、外周血管疾病和心功能受损患者的进一步研究正在进行中，以证实和扩展目前的研究结果。
